Pharma Journalist -

Lonza Pharma and Biotech and Denali Therapeutics asserted having entered into a strategic partnership on Denali's biologic pipeline products for neurodegenerative diseases.The agreement…
Read More...

Roche and Flatiron Health asserted that the two partners have ventured into a definitive agreement enumerating that Roche will acquire all shares of Flatiron  Health from an existing…
Read More...

AbbVie asserted results from the double-blinded extension phase of the Phase 2 CELEST Study, exhibiting that many patients treated with upadacitinib who attained clinical response after…
Read More...

Great Point Partners, LLC submitted a letter to the Board of Directors of BioCryst Pharmaceuticals strongly rebuking BCRX's merger with Idera Pharmaceuticals. The letter states "We…
Read More...

Novartis declared additional results from the SCULPTURE study marking that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx exhibited zero impact of skin…
Read More...

Global leader in non-invasive molecular dermatology, DermTech claimed that the late-breaking abstract, "Validation of Noninvasive Gene Expression (PLA) Against High Risk Driver…
Read More...

 Photocure ASA asserted that the U.S Food and Drug Administration approved its supplemental new drug application to extend the indication for Blue Light Cystoscopy with Cysview to…
Read More...

AstraZeneca and MedImmune proclaimed that the US FDA has approved IMFINZI  (durvalumab) for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC)…
Read More...

Cell Medica, asserted the appointment of Kevin S. Boyle, Sr as the Chief Financial Officer, based in Houston, TX.  Kevin S. Boyle ushers on board 20 years of financial and capital…
Read More...

Teva Pharmaceutical Industries asserted the commercial availability of QVAR RediHaler Inhalation Aerosol to patients in both 40 mcg and 80 mcg strengths by prescription in the U.S QVAR…
Read More...